SpectronRx, a leading radiopharmaceutical contract development and manufacturing organization (CDMO), recently announced that the U.S. Nuclear Regulatory Commission (NRC) issued a Materials License for its new Indianapolis, IN headquarters. The license expands SpectronRx's roster of authorized nuclear pharmacists and authorized users. The news comes as SpectronRx continues to scale up its early-stage development and commercialization services for leading pharmaceutical companies working to develop and deploy radiopharmaceutical compounds for the treatment and detection of certain cancers and other diseases.

SpectronRx now has two Indiana locations. SpectronRx opened its South Bend facility in 2016, and has now relocated its headquarters to the new Indianapolis location. SpectronRx also has plans to expand into the European Union. The NRC materials license authorizes SpectronRx to receive, acquire, possess and transfer byproducts, sources, and special nuclear material in chemical and/or physical form. This includes any byproduct material with Atomic Numbers 1 through to 83 with a half-life of less than or equal to 120 days, with some exceptions. The license lists more than 25 different isotopes, ranging from Lutetium-177, Actinium-225, Iodine-131,and Iodine-123. Authorized uses include the preparation and distribution of radioactive drugs and radio-chemicals for medical use to authorized recipients.

To read more please visit:

https://www.dotmed.com/news/story/55389

Source: Healthcare Business news